Study Summary
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to recognize and target the PSCA tumor marker on cancer cells.
Want to learn more about this trial?
Request More InfoInterventions
BPX-601BIOLOGICAL
Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
RimiducidDRUG
Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | United States |
| Emory Winship Cancer Institute | Atlanta | Georgia | United States |
| Rush University Medical Center | Chicago | Illinois | United States |
| University of Chicago Medicine | Chicago | Illinois | United States |
| Karmanos Cancer Institute | Detroit | Michigan | United States |
| University of Nebraska | Omaha | Nebraska | United States |
| John Theurer Cancer Center, Hackensack University Medical Center | Hackensack | New Jersey | United States |
| Roswell Park Cancer Institute | Buffalo | New York | United States |
| Columbia University Medical Center | New York | New York | United States |
| Duke University | Durham | North Carolina | United States |
| Thomas Jefferson University | Philadelphia | Pennsylvania | United States |
| Baylor Sammons Cancer Center | Dallas | Texas | United States |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | United States |